- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05293314
Assessment of an Exhaled Breath Test to Detect Bronchiectasis
Assessment of an Exhaled Breath Test Using High-Pressure Photon Ionization Time-of-Flight Mass Spectrometry to Detect Bronchiectasis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Li-Chao Fan, MD
- Phone Number: +86 17701833807
- Email: fanlichao2012@126.com
Study Contact Backup
- Name: Jin-fu Xu, MD
- Phone Number: +86 13321922898
- Email: jfxucn@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200433
- Recruiting
- Shanghai Pulmonary Hospital
-
Contact:
- Jin-Fu Xu
- Phone Number: 13321922898
- Email: jfxucn@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients were recruited according to the following inclusion criteria: (1) Age>18 years, the diagnosis of bronchiectasis need reference to the definition of "idiopathic bronchiectasis" according to British Thoracic Society in 2010 or 2012 China bronchiectasis expert consensus; (2) Patients are clinically diagnosed as acute attack (AE) and need hospitalization, that is, they have the following three or more clinical symptoms within 48 hours: Cough; Changes in the amount or character of sputum; Purulent sputum; Shortness of breath or decreased exercise tolerance; weakness hemoptysis; (3) Patient quit smoking for more than two years; (4) Willing to join in and sign the informed consent form.
Control subjects were recruited according to the following inclusion criteria:(1) Age>18 years; (2) No history of any lung disease (except for the history of pneumonia in the past time and small pulmonary nodules); (3) Willing to join in and sign the informed consent form.
Exclusion Criteria:
Patients were excluded according to the following criteria: (1) Bronchiectasis is caused by known causes: previous respiratory tract infections (especially measles and pertussis in dead infants and children, immune function defects (such as hypoimmunoglobulinemia, chronic granulomatous diseases, complement defects, HIV, etc.), genetic factors (such as ciliary dyskinesia, cystic pulmonary fibrosis, cartilage defects, etc.), airway obstruction and repeated aspiration; (2) Patients with a history of other respiratory diseases (cystic fibrosis, allergic bronchopulmonary aspergillosis, asthma, 1-antitrypsin deficiency, pulmonary tuberculosis, COPD, lung cancer, interstitial lung disease)and atopic diseases were excluded; (3) Serious comorbidities (chronic renal failure, hepatic disease, etc.) ; (4) Patients who are currently smoking or have quit smoking for less than 2 years; (5) Women who are pregnant or preparing for pregnancy or breastfeeding; (6) Participated in other clinical trials within three months.
Control subjects were excluded according to the following criteria: (1) Previous history of malignant tumor; (2) presence of active infections (such as tuberculosis, non-tuberculous mycobacterium disease) or liver disease; (3) women who are pregnant or preparing for pregnancy and are breastfeeding; (4) Current smoking, or smoking cessation less than 2 years.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with bronchiectasis
Diagnosis of bronchiectasis was performed using chest HRCT scans in suspected patients with coughing and expectoration, or long durations of haemoptysis.
High-resolution images were obtained during full inspiration at 1-mm collimation and 10-mm intervals from the apex to the base of the lungs.
The presence of bronchiectasis was confirmed based on the following criteria: 1) lack of tapering in the bronchi; 2) dilation of the bronchi where the internal diameter was larger than that of the adjacent pulmonary artery; or 3) visualisation of the peripheral bronchi within 1 cm of the costal pleural surface or the adjacent mediastinal pleural surface.
|
All exhaled breath samples were collected by trained investigators following the same protocol.
All participants fasted for at least 6 hours before breath collection.
To reduce potential confounding factors, all participants were asked to not ingest spicy food, alcohol, or coffee the night before exhaled breath collection.
Exhaled breath was collected in Tedlar air bags (DuPont de Nemours).
The night before breath collection, the Tedlar bags were baked at 60 °C for 3 hours to fully release possible contaminants and continuously purged with high-purity nitrogen 4 times.
Participants first gargled with pure water and then performed a single deep nasal inhalation followed by complete exhalation via their mouth into Tedlar bags.
A total of 1000 mL of exhaled breath was collected from each participant.
|
Healthy control group
Control group is healthy participants.
|
All exhaled breath samples were collected by trained investigators following the same protocol.
All participants fasted for at least 6 hours before breath collection.
To reduce potential confounding factors, all participants were asked to not ingest spicy food, alcohol, or coffee the night before exhaled breath collection.
Exhaled breath was collected in Tedlar air bags (DuPont de Nemours).
The night before breath collection, the Tedlar bags were baked at 60 °C for 3 hours to fully release possible contaminants and continuously purged with high-purity nitrogen 4 times.
Participants first gargled with pure water and then performed a single deep nasal inhalation followed by complete exhalation via their mouth into Tedlar bags.
A total of 1000 mL of exhaled breath was collected from each participant.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The accuracy of breathomics to distinguish bronchiectasis from healthy people
Time Frame: one year
|
The accuracy of breathomics to distinguish bronchiectasis from healthy people was measured by the sensitivity, specificity, accuracy, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve.
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of the bronchiectasis severity according to breathomics
Time Frame: 30 days
|
The severity of bronchiectasis was based on the BSI score and E-FACED score.
Multivariable Logistic Regression Analyses would be used for the relationship between breathomics and the severity of bronchiectasis.
|
30 days
|
Collaborators and Investigators
Investigators
- Study Director: Jin-fu Xu, MD, Department of Respiratory and Critical Care
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20220303
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiectasis
-
Ruijin HospitalAstraZeneca Investment (China) Co., LtdNot yet recruitingBronchiectasis AdultChina
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Fondazione Policlinico Universitario Agostino Gemelli IRCCS; IRCCS Azienda... and other collaboratorsActive, not recruiting
-
University of Sao Paulo General HospitalEnrolling by invitation
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompletedBronchiectasis AdultBrazil
-
University of North Carolina, Chapel HillCompletedBronchiectasis AdultUnited States
-
Seoul National University Bundang HospitalUnknownSymptomatic BronchiectasisKorea, Republic of
-
Chang Gung Memorial HospitalNot yet recruitingBronchiectasis AdultTaiwan
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruitingBronchiectasis Adult
-
University of DundeeRecruitingBronchiectasis AdultUnited Kingdom
-
Papworth Hospital NHS Foundation TrustGlaxoSmithKlineCompletedBronchiectasis | Idiopathic BronchiectasisUnited Kingdom
Clinical Trials on an exhaled breath test
-
Mebo Research, Inc.Aurametrix; Menssana Research, Inc.CompletedNutritional and Metabolic DiseasesUnited States, United Kingdom
-
Gadjah Mada UniversityRecruiting
-
Gadjah Mada UniversityCompleted
-
University Hospital, AntwerpNot yet recruitingBronchopulmonary Dysplasia
-
Stanford UniversityCompletedSmall Cell Lung Cancer | Non-Small Cell Lung Cancer | Lung CancerUnited States
-
Azienda Ospedaliera Universitaria Policlinico Paolo...Recruiting
-
Gazi UniversityThe Scientific and Technological Research Council of TurkeyUnknownExhaled Breath Condensate
-
University of FloridaCompleted
-
Fundació Institut de Recerca de l'Hospital de la...Unknown
-
Seoul National University HospitalUnknownGastrointestinal Hemorrhage | Volatile Organic CompoundsKorea, Republic of